 Connection
Charles Edelstein to TOR Serine-Threonine Kinases
This is a "connection" page, showing publications Charles Edelstein has written about TOR Serine-Threonine Kinases.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.090 |
|
|
|
-
Atwood DJ, He Z, Miyazaki M, Hopp K, Jani A, Furgeson SB, Faubel S, Edelstein CL. mTOR promotes the formation and growth of tertiary lymphoid tissues in the kidney. Front Immunol. 2025; 16:1527817.
Score: 0.703
-
Atwood DJ, Pokhrel D, Brown CN, Holditch SJ, Bachu DM, Thorburn A, Hopp K, Edelstein CL. Increased mTOR and suppressed autophagic flux in the heart of a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease. Cell Signal. 2020 10; 74:109730.
Score: 0.503
-
Holditch SJ, Brown CN, Atwood DJ, Lombardi AM, Nguyen KN, Toll HW, Hopp K, Edelstein CL. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol. 2019 07 01; 317(1):F187-F196.
Score: 0.461
-
Ravichandran K, Zafar I, Ozkok A, Edelstein CL. An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease. Nephrol Dial Transplant. 2015 Jan; 30(1):45-53.
Score: 0.335
-
Ravichandran K, Zafar I, He Z, Doctor RB, Moldovan R, Mullick AE, Edelstein CL. An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2. Hum Mol Genet. 2014 Sep 15; 23(18):4919-31.
Score: 0.327
-
Belibi F, Ravichandran K, Zafar I, He Z, Edelstein CL. mTORC1/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease. Am J Physiol Renal Physiol. 2011 Jan; 300(1):F236-44.
Score: 0.255
-
Atwood D, He Z, Miyazaki M, Hailu F, Klawitter J, Edelstein CL. Early treatment with 2-deoxy-d-glucose reduces proliferative proteins in the kidney and slows cyst growth in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease (PKD). Cell Signal. 2024 11; 123:111351.
Score: 0.166
-
Davis S, Gralla J, Chan L, Wiseman A, Edelstein CL. Effect of Sirolimus on Native Total Kidney Volume After Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Pilot Study. Transplant Proc. 2018 Jun; 50(5):1243-1248.
Score: 0.108
-
Zafar I, Ravichandran K, Belibi FA, Doctor RB, Edelstein CL. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease. Kidney Int. 2010 Oct; 78(8):754-61.
Score: 0.063
-
Belibi FA, Edelstein CL. Novel targets for the treatment of autosomal dominant polycystic kidney disease. Expert Opin Investig Drugs. 2010 Mar; 19(3):315-28.
Score: 0.061
-
Edelstein CL. Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease. Clin J Am Soc Nephrol. 2008 Jul; 3(4):1219-26.
Score: 0.054
-
Edelstein CL. Therapeutic interventions for autosomal dominant polycystic kidney disease. Nephrol News Issues. 2008 Mar; 22(3):25-6.
Score: 0.053
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|